HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Rational design of PIN1 inhibitors for cancer treatment based on conformational diversity analysis and docking based virtual screening.

Abstract
The parvulin PIN1 (peptidyl-prolyl cis-trans isomerase NIMA-interacting 1), is the only enzyme capable of isomerizing prolines of phospho-Serine/Threonine-Proline motifs. PIN1 binds to a subset of proteins and plays an essential role in regulating protein function post-phosphorylation control. Furthermore, the activity of PIN1 regulates the outcome of the signalling of proline-directed kinases (e.g. MAPK, CDK, or GSK3) and thus regulates cell proliferation and cell survival. For these reasons, PIN1 inhibitors are interesting since they may have therapeutic implications for cancer. Several authors have already reported that the non-structural point mutation Trp34Ala prevents PIN1 from interacting with its downstream effector proteins. In this work, we characterized PIN1 structurally, intending to explore new inhibition targets for the rational design of pharmacological activity compounds. Through a conformational diversity analysis of PIN1, we identified and characterized a highly specific druggable pocket around the residue Trp34. This pocket was used in a high-throughput docking screening of 450,000 drug-like compounds, and the top 10 were selected for re-docking studies on the previously used conformers. Finally, we evaluated the binding of each compound by thermal shift assay and found four molecules with a high affinity for PIN1 and potential inhibitory activity. Through this strategy, we achieved novel drug candidates with the ability to interfere with the phosphorylation-dependent actions of PIN1 and with potential applications in the treatment of cancer.Communicated by Ramaswamy H. Sarma.
AuthorsJulián Maggio, Maia Cabrera, Romina Armando, Patricio Chinestrad, Marina Pifano, Pablo Lorenzano Menna, Daniel E Gomez, Diego L Mengual Gómez
JournalJournal of biomolecular structure & dynamics (J Biomol Struct Dyn) Vol. 40 Issue 13 Pg. 5858-5867 (Aug 2022) ISSN: 1538-0254 [Electronic] England
PMID33463409 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Enzyme Inhibitors
  • NIMA-Interacting Peptidylprolyl Isomerase
  • Proline
  • PIN1 protein, human
Topics
  • Antineoplastic Agents (chemistry, pharmacology)
  • Early Detection of Cancer
  • Enzyme Inhibitors (chemistry, pharmacology)
  • Humans
  • NIMA-Interacting Peptidylprolyl Isomerase (antagonists & inhibitors, genetics)
  • Neoplasms (drug therapy, genetics)
  • Phosphorylation
  • Proline (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: